Zasocitinib
- Generic Name
- Zasocitinib
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 268
- Registration Number
- NCT06233461
- Locations
- πΊπΈ
GastroIntestinal BioSciences, Los Angeles, California, United States
πΊπΈUnited Medical Doctors, Murrieta, California, United States
πΊπΈUCI Health, Orange, California, United States
A Study of TAK-279 in Healthy Chinese Adults
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT06111547
- Locations
- π¨π³
Huashan Hospital Fudan University, Shanghai, China
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1108
- Registration Number
- NCT06108544
- Locations
- πΊπΈ
Advanced Medical Research, PC, Atlanta, Georgia, United States
π¨π¦Skinsense Medical Research - 411 2nd Ave N - Probity - PPDS, Saskatoon, Saskatchewan, Canada
π΅π±ETG Siedlce - PPDS, Siedlce, Mazowieckie, Poland
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 693
- Registration Number
- NCT06088043
- Locations
- πΊπΈ
Saguaro Dermatology Associates, LLC - Probity - PPDS, Phoenix, Arizona, United States
πΊπΈFirst OC Dermatology - Fountain Valley, Fountain Valley, California, United States
πΊπΈCenter for Dermatology Clinical Research, Fremont, California, United States
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 172
- Registration Number
- NCT05995249
- Locations
- πΊπΈ
Celerion - Tempe, AZ Site, Tempe, Arizona, United States
A Study of TAK-279 in Adults With or Without Kidney Problems
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT05992155
- Locations
- πΊπΈ
Research by Design, Chicago, Illinois, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
πΊπΈClinical Pharmacology of Miami, Miami, Florida, United States
A Study of TAK-279 in Adults With or Without Liver Damage
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT05976321
- Locations
- πΊπΈ
University of Miami, Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
πΊπΈAmerican Research Corporation - Texas Liver Institute, San Antonio, Texas, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 305
- Registration Number
- NCT05153148
- Locations
- π΅π±
Nimbus site #XYZ, Wroclaw, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.